Hormonal
Tirzepatide treatment does not increase the risk of major adverse cardiovascular events (MACE-4) in patients with type 2 diabetes compared to control groups.
If you have type 2 diabetes, taking tirzepatide once a week does not increase your risk of heart attacks, strokes, or cardiovascular death compared to other standard treatments. This holds true for patients with both low and high existing heart risk, providing a safe option for cardiovascular protection while managing blood sugar.
Tirzepatide did not increase the risk of major cardiovascular events in participants with T2D versus controls.
Why this rating
Pre-specified meta-analysis of 7 randomized controlled trials with centrally adjudicated endpoints and a large sample size (n=7,215).
Source
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
Naveed Sattar et al. · Nature Medicine · 2022
DOI 10.1038/s41591-022-01707-4
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →